HURA TuHURA Biosciences Q4 2025 EPS trails estimates by 282 percent shares slip 141 percent in todays trading LivaNova PLC LIVN shares climb 7 percent after beating earnings estimates with 71 percent EPS surprise and 107 percent revenue growth DXP DXPE Q4 earnings beat masks deeper concerns as stock tanks 17 despite 119 revenue growth The regulatory exposure in VYNE Therapeutics VYNE results Q4 2025 Earnings Beat Estimates